Modafinil
Provigil
Modafinil (Provigil) is an oral wakefulness-promoting agent (eugeroic) FDA-approved for excessive sleepiness in narcolepsy, obstructive sleep apnea (as adjunct to CPAP), and shift-work sleep disorder, and widely used off-label as a cognitive enhancer. The main risks, which should guide any decision to use it, are (1) rare but potentially fatal serious skin/hypersensitivity reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS are described in regulatory labeling and postmarketing surveillance, and a pediatric trial program documented a case of possible erythema multiforme/Stevens-Johnson syndrome — that mandate stopping at the first sign of any rash; (2) a real, human-confirmed abuse/dependence signal because it blocks the dopamine transporter and raises dopamine in the nucleus accumbens to a degree comparable to methylphenidate; (3) sympathomedullary activation that raises heart rate and blood pressure, making it hazardous in cardiovascular disease; and (4) neuropsychiatric events including anxiety, insomnia, and — even at low doses in vulnerable people — mania and psychosis. It induces CYP3A4 and can cause hormonal contraceptives to fail. It is not an anabolic/hormonal agent and does not build muscle. This monograph leads with risk and is not a recommendation to use; anyone using or considering modafinil should do so under a clinician with monitoring.
Mechanism of action
Pharmacokinetics
Approximately 12-15 hours (racemic modafinil), largely reflecting the longer-lived l-enantiomer; the R-enantiomer, armodafinil, is longer-lived.
Peak plasma concentration at ~2-4 hours after oral dosing; wake-promoting effect spans roughly the waking day, supporting once-daily (morning) dosing. Steady state reached in 2-4 days.
Oral (tablet).
Extensively metabolized, primarily in the liver, mainly by amide hydrolysis with lesser CYP-mediated oxidation; less than 10% excreted unchanged in urine. Modafinil induces CYP3A4 (and CYP1A2, CYP2B6) and inhibits CYP2C19/suppresses CYP2C9, creating drug-interaction risk. Clearance is reduced in hepatic impairment, renal impairment, and the elderly, warranting dose reduction and clinician oversight. This PK information is for washout and monitoring planning, not for evading testing.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Reduces excessive daytime sleepiness and increases objective wakefulness (Maintenance of Wakefulness Test, Multiple Sleep Latency Test) and subjective sleepiness (Epworth Sleepiness Scale) in narcolepsy at 200-400 mg/day
- Improves daytime sleepiness in obstructive sleep apnea (adjunct to CPAP, not a substitute) and shift-work sleep disorder
- In healthy non-sleep-deprived people, modestly and inconsistently enhances executive function and attention, especially on more complex tasks; effects on learning/memory are mixed and some studies report impaired divergent/creative thinking
- Does not disrupt nocturnal sleep architecture at therapeutic doses
- Did not improve fatigue in primary biliary cirrhosis in a controlled trial, illustrating that eugeroic effect does not generalize to all fatigue states
Adverse effects by system
Sympathomedullary activation: in a randomized crossover study 400 mg raised resting heart rate ~9 bpm, systolic BP ~7 mmHg and diastolic BP ~5 mmHg, with increased urinary/plasma catecholamines. Pooled RCT safety data found clinically significant BP or HR increases were infrequent (<1%) at 200-400 mg, but palpitations, tachycardia, and blood-pressure elevation are recognized. Caution/contraindication in cardiovascular disease.
No signal of clinically significant hepatotoxicity in pooled RCT data (clinically meaningful lab abnormalities in <1% of patients). Modafinil is heavily hepatically metabolized, so clearance falls in hepatic impairment (dose reduction advised). Serious liver injury is not an established characteristic effect.
Modafinil is not a hormonal or anabolic agent and has no described mechanism for suppressing the hypothalamic-pituitary-testicular/gonadal axis; no adequate human data show clinically meaningful HPTA or testosterone suppression. The clinically important endocrine interaction is CYP3A4 induction lowering ethinylestradiol exposure, which can cause hormonal contraceptive failure.
Possible teratogenicity: evidence is conflicting. A large multicenter (ENTIS) case series did not find an increased rate of major congenital anomalies but observed a tendency toward lower birth weight and smaller neonatal head circumference; regulatory bodies issued alerts about major congenital malformations with first-trimester exposure. Modafinil should not be used in pregnancy, and it reduces hormonal contraceptive reliability. No robust human fertility data.
Anxiety, nervousness, insomnia, irritability, and headache are common. More serious but less frequent: mania and psychosis, reported even at low doses (100 mg/day) and in previously healthy individuals as well as in those with bipolar disorder or schizophrenia. Suicidal ideation and aggression have been described in labeling.
No characteristic nephrotoxicity. Renal impairment slows elimination, so dosing should be reduced and supervised by a clinician; less than 10% is renally excreted unchanged.
No characteristic clinically significant hematologic effect; pooled RCT laboratory data showed abnormalities in <1% of patients. Rare eosinophilia can accompany DRESS-type hypersensitivity.
Rash is reported in trials. Serious, potentially life-threatening cutaneous/hypersensitivity reactions — Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS (multi-organ hypersensitivity), and angioedema — are described in regulatory labeling and postmarketing surveillance. A pediatric ADHD trial program documented one case of possible erythema multiforme/Stevens-Johnson syndrome during pivotal studies, and regulators subsequently requested additional studies to better evaluate the risk of severe cutaneous adverse reactions before pediatric approval could proceed. No adequately powered primary PubMed-indexed trial quantifies overall incidence, so the rate is uncertain but the consequence is severe. Any rash warrants immediate discontinuation and medical evaluation.
HPTA suppression & recovery
Suppression: None expected / not applicable
Modafinil is a eugeroic, not an anabolic-androgenic steroid, SERM, or other hormonal agent, and has no described mechanism for suppressing the hypothalamic-pituitary-gonadal axis; there is no adequate human evidence of clinically meaningful HPTA or testosterone suppression, so no SERM-based post-cycle recovery framing applies. Anyone with symptoms of low testosterone or hormonal disturbance, or who is combining modafinil with agents that do suppress the axis, should have this evaluated and managed by an endocrinologist rather than self-treating; single-SERM therapy, if ever considered for a genuinely suppressed axis, is an endocrinologist's decision, and dual-SERM protocols are not appropriate.
Monitoring
Cadence: Cardiovascular vitals at baseline, after initiation/dose change, and periodically thereafter; clinical psychiatric review at each visit; immediate unscheduled evaluation for any rash, mucosal lesion, facial swelling, or psychiatric change.
- Any skin rash, blistering, mucosal (mouth/eye/genital) lesions, facial or throat swelling, or fever with rash: stop immediately and seek emergency care (possible SJS/TEN/DRESS)
- Chest pain, palpitations, fainting, or markedly elevated blood pressure
- New or worsening anxiety, agitation, hallucinations, paranoia, mania, or suicidal thoughts
- Signs of dependence: escalating dose, craving, use to get high rather than for a sleep disorder
- Unexpected pregnancy or breakthrough bleeding on hormonal contraception (possible contraceptive failure)
Contraindications
- Known hypersensitivity to modafinil or armodafinil, or any prior rash/hypersensitivity reaction to either
- History of serious skin reaction (SJS/TEN/DRESS) with modafinil/armodafinil
- Clinically significant cardiovascular disease: recent myocardial infarction, unstable angina, uncontrolled hypertension, serious arrhythmia; history of left ventricular hypertrophy or mitral valve prolapse syndrome with prior CNS-stimulant use
- Pregnancy (major-congenital-malformation concern and reduced fetal growth signal) and reliance on hormonal contraception alone (CYP3A4 induction can cause contraceptive failure)
- History of psychosis, mania, or bipolar disorder: risk of precipitating psychosis/mania even at low doses
- History of stimulant misuse or substance use disorder, given human-confirmed abuse liability
- Significant hepatic impairment without dose reduction and specialist oversight
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- This is a risk summary, not an endorsement: if you have a sleep disorder, modafinil belongs under a clinician who can diagnose the cause and monitor you, not self-directed use.
- Stop the drug and seek urgent medical care at the first sign of any rash, mouth/eye/genital sores, facial swelling, or fever with rash. Serious skin reactions (SJS/TEN/DRESS) can be fatal and are the single most important reason to discontinue immediately.
- Do not use if you have significant heart disease, uncontrolled hypertension, or arrhythmia; check blood pressure and heart rate before and during use, and stop for chest pain, palpitations, or fainting.
- If you have any history of bipolar disorder, mania, or psychosis, the risk of precipitating a psychiatric emergency is real even at low doses; involve a psychiatrist before considering use.
- If you rely on hormonal birth control, modafinil can make it fail: use an additional or non-hormonal method during use and for a month after stopping; avoid entirely in pregnancy or if trying to conceive.
- Recognize dependence risk: because it raises dopamine like methylphenidate, escalating doses, cravings, or using it to feel high rather than to manage sleepiness are signals to stop and seek help.
- Beware drug interactions: it lowers levels of many CYP3A4 substrates and raises CYP2C19 substrates; review every medication and supplement with a pharmacist or physician.
- Do not combine with other stimulants or use to push through severe sleep deprivation; unmanaged sleep loss carries its own cardiovascular and cognitive dangers.
- Reduce dose and get specialist oversight if you have liver or kidney impairment or are older, since the drug clears more slowly.
Citations (19)
Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.
- 01
Modafinil significantly reduces excessive daytime sleepiness in narcolepsy (200 and 400 mg/day) on Epworth Sleepiness Scale, Maintenance of Wakefulness Test and MSLT, without disrupting nocturnal sleep; 400 mg associated with more nausea/nervousness.
- 02
US 18-center randomized placebo-controlled trial: modafinil 200/400 mg improved all subjective and objective sleepiness measures in narcolepsy; headache the main adverse event.
- 03
Meta-analysis of RCTs shows modafinil and armodafinil significantly improve Epworth Sleepiness Scale and Maintenance of Wakefulness Test sleep latency in obstructive sleep apnea; generally tolerated.
Meta-analysisDOI 10.1016/j.clinthera.2016.02.004 ↗
- 04
In a double-blind RCT modafinil reduced excessive daytime sleepiness (ESS) versus placebo in narcolepsy; treatment-related adverse events occurred (comparator arm).
- 05
In healthy non-sleep-deprived humans modafinil inconsistently enhances executive function/attention, with mixed learning/memory effects and some impairment of divergent creative thinking; indirectly raises cortical catecholamines and modulates orexin/histamine/glutamate/serotonin/GABA.
- 06
Modafinil did not improve fatigue versus placebo in primary biliary cirrhosis; adverse events included headache, diarrhea, and rash.
- 07
Elimination half-life ~12-15 h; Tmax 2-4 h; extensive hepatic metabolism mainly by amide hydrolysis; <10% excreted unchanged; clearance reduced in hepatic/renal impairment and elderly; induces CYP3A4/1A2/2B6, inhibits CYP2C19.
- 08
Modafinil induces CYP3A4/5 in vivo, decreasing exposure to ethinylestradiol and triazolam — basis for hormonal contraceptive failure risk.
- 09
Armodafinil (R-modafinil) is a moderate CYP3A4 inducer and CYP2C19 inhibitor in healthy subjects, altering exposure of co-administered substrates.
- 10
Pooled safety of 6 RCTs (n=1529): most common AEs headache, nausea; clinically significant BP/HR/ECG changes and lab abnormalities each <1%; no effect on sleep architecture.
- 11
Randomized crossover study: modafinil 400 mg raised heart rate ~9.2 bpm, systolic BP ~7.3 mmHg, diastolic BP ~5.3 mmHg with increased catecholamines (sympathomedullary activation); caution in cardiovascular disease.
- 12
Human PET: modafinil blocks dopamine transporters and increases extracellular dopamine in caudate, putamen, and nucleus accumbens, indicating potential for abuse and dependence.
- 13
Human PET DAT-occupancy study: modafinil striatal DAT occupancy ~51-57% at 200-300 mg, comparable to methylphenidate, consistent with non-trivial abuse liability.
- 14
Placebo-controlled RCT for nicotine dependence: modafinil did not improve quit rates and increased negative affect and withdrawal symptoms.
- 15
Modafinil-induced psychosis reported in a previously healthy person at 100 mg/day, without prior psychiatric/medical history or shift work.
Case reportDOI 10.5152/npa.2015.7160 ↗
- 16
Modafinil-induced psychosis at 100 mg/day within 2 days in a bipolar-depression patient already on mood stabilizers and antipsychotics.
Case reportDOI 10.1155/2018/3732958 ↗
- 17
Multicenter ENTIS case series: no increased rate of major congenital anomalies after first-trimester modafinil exposure but a tendency toward lower birth weight and smaller neonatal head circumference; advises against use in pregnancy.
Case seriesDOI 10.1111/acps.13643 ↗
- 18
Regulatory alerts raised concern for major congenital malformations with modafinil during organogenesis; epidemiological evidence is conflicting and treatment is best suspended in early pregnancy pending better data.
- 19
A pediatric ADHD trial program (modafinil film-coated tablets, n=933) documented one case of possible erythema multiforme/Stevens-Johnson syndrome during the pivotal studies, prompting regulators to request additional studies to better evaluate the risk of severe cutaneous adverse reactions.
ReviewPMID 19300563 ↗
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice